Wegovy: For Wegovy, the STEP 1 clinical trial showed the following outcomes over 68 weeks for participants with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related medical condition, other than diabetes: 2.4 mg semaglutide: 14.9% weight reduction with 86.4% of participants achieving at least a 5% weight loss, and about 70% achieving a weight loss of at least 10%
Use Boundary Research use only
Temporary and reversible: the follicles stay intact, and most people recover even without stopping treatment
Anti-Inflammatory Modulation BPC-157 reduces levels of inflammatory markers including IL-6, TNF-alpha, and COX-2 expression
Biolegend), PE Siglec-F (1:100
They don't seem like they're that big of a thing to do, but to [00:03:00] us, they are huge